Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20636003rdf:typepubmed:Citationlld:pubmed
pubmed-article:20636003lifeskim:mentionsumls-concept:C0472699lld:lifeskim
pubmed-article:20636003lifeskim:mentionsumls-concept:C0079613lld:lifeskim
pubmed-article:20636003lifeskim:mentionsumls-concept:C0439662lld:lifeskim
pubmed-article:20636003lifeskim:mentionsumls-concept:C0725066lld:lifeskim
pubmed-article:20636003pubmed:issue4lld:pubmed
pubmed-article:20636003pubmed:dateCreated2010-7-19lld:pubmed
pubmed-article:20636003pubmed:abstractTextAlthough partially HLA-mismatched hematopoietic stem cell transplantation (HSCT) has become an important therapeutic option for children with primary immunodeficiencies, delayed reconstitution of the T-cell compartment remains a major clinical concern. Adoptive immunotherapies to provide recipients with a protective and diverse T-cell repertoire in the months following HSCT are warranted. In order to improve T-cell reconstitution after T-cell-depleted HSCT, different strategies are currently being studied. Some are based on administration of modified mature T cells (e.g., allodepleted T cells or pathogen-specific T cells). Others aim at accelerating de novo thymopoiesis from donor-derived hematopoietic stem cells in vivo via the administration of thymopoietic agents or the transfer of large numbers of T-cell precursors generated ex vivo. The present article will provide a brief summary of recent advances in the field of allodepletion and adoptive transfer of pathogen-specific T cells and a detailed discussion of strategies for enhancing thymopoiesis in vivo.lld:pubmed
pubmed-article:20636003pubmed:languageenglld:pubmed
pubmed-article:20636003pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20636003pubmed:citationSubsetIMlld:pubmed
pubmed-article:20636003pubmed:statusMEDLINElld:pubmed
pubmed-article:20636003pubmed:monthJullld:pubmed
pubmed-article:20636003pubmed:issn1750-7448lld:pubmed
pubmed-article:20636003pubmed:authorpubmed-author:FischerAlainAlld:pubmed
pubmed-article:20636003pubmed:authorpubmed-author:Cavazzana-Cal...lld:pubmed
pubmed-article:20636003pubmed:authorpubmed-author:André-Schmutz...lld:pubmed
pubmed-article:20636003pubmed:authorpubmed-author:Hacein-Bey-Ab...lld:pubmed
pubmed-article:20636003pubmed:authorpubmed-author:Dal...lld:pubmed
pubmed-article:20636003pubmed:authorpubmed-author:ReimannChrist...lld:pubmed
pubmed-article:20636003pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20636003pubmed:volume2lld:pubmed
pubmed-article:20636003pubmed:ownerNLMlld:pubmed
pubmed-article:20636003pubmed:authorsCompleteYlld:pubmed
pubmed-article:20636003pubmed:pagination481-96lld:pubmed
pubmed-article:20636003pubmed:meshHeadingpubmed-meshheading:20636003...lld:pubmed
pubmed-article:20636003pubmed:meshHeadingpubmed-meshheading:20636003...lld:pubmed
pubmed-article:20636003pubmed:meshHeadingpubmed-meshheading:20636003...lld:pubmed
pubmed-article:20636003pubmed:meshHeadingpubmed-meshheading:20636003...lld:pubmed
pubmed-article:20636003pubmed:meshHeadingpubmed-meshheading:20636003...lld:pubmed
pubmed-article:20636003pubmed:year2010lld:pubmed
pubmed-article:20636003pubmed:articleTitleAdvances in adoptive immunotherapy to accelerate T-cellular immune reconstitution after HLA-incompatible hematopoietic stem cell transplantation.lld:pubmed
pubmed-article:20636003pubmed:affiliationInstitut National de la Santé et de la Recherche Médicale (INSERM), Département de Biothérapie, Hopital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, and Université Paris Descartes 75015 Paris, France.lld:pubmed
pubmed-article:20636003pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20636003pubmed:publicationTypeReviewlld:pubmed
pubmed-article:20636003pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed